Difelikefalin Acetate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 0.5 mg/mL , 1 mg/mL
Reference Brands: Korsuva (USA)
Category:
Critical Care
Difelikefalin Acetate is available in Injection
and strengths such as 0.5 mg/mL , 1 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Difelikefalin Acetate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Difelikefalin Acetate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Difelikefalin, marketed under the brand name Korsuva, is a peripherally acting opioid peptide used for the treatment of moderate to severe pruritus (itch) associated with chronic kidney disease in patients undergoing hemodialysis. It is a highly selective agonist of the κ-opioid receptor (KOR) that acts predominantly outside the central nervous system, minimizing typical opioid-related side effects.
The mechanism of action of difelikefalin involves dual pathways. By activating KORs on peripheral nerve terminals, it inhibits ion channels responsible for transmitting pain and itch signals, reducing the perception of discomfort. Additionally, it activates KORs expressed by certain immune cells, leading to decreased release of proinflammatory and nerve-sensitizing mediators such as prostaglandins. This combined action helps alleviate itch while addressing the underlying inflammatory component.
Difelikefalin is administered as an intravenous injection during hemodialysis sessions under specialist supervision. Its peripherally restricted activity, targeted mechanism, and favorable safety profile make it a valuable therapeutic option for improving quality of life in patients with chronic kidney disease-associated pruritus, especially in populations where conventional therapies may be less effective or poorly tolerated.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing